GlassScriptPhysician profile
Kristin Schmidt
NPI 1578181210
$11,667.49
in general payments reported to CMS, 2019-2025
65 companies · $2,694 in 2025
The $2,694 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,088 · 2022: $1,764 · 2023: $3,632 · 2024: $2,489 · 2025: $2,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,463 · Consulting Fee: $1,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,462.70 |
| Consulting Fee | $1,352.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,030.14 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $844.84 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $726.00 | 2021-2025 | Imfinzi, Enhertu, Calquence |
| Janssen Biotech, INC. | $478.64 | 2021-2025 | Rybrevant, Darzalex, Erleada |
| Genzyme Corporation | $383.83 | 2021-2025 | |
| Seagen INC. | $371.97 | 2021-2023 | Tukysa, Adcetris, Tivdak |
| Eisai INC. | $363.30 | 2021-2025 | |
| Daiichi Sankyo INC. | $358.35 | 2022-2025 | Enhertu, Vanflyta |
| Pfizer INC. | $344.06 | 2022-2025 | |
| Merz North America, INC. | $320.25 | 2023-2025 | Xeomin |
| Bayer Healthcare Pharmaceuticals INC. | $298.71 | 2021-2025 | |
| Glaxosmithkline, LLC. | $280.63 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Lilly USA, LLC | $262.46 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Celgene Corporation | $252.36 | 2022-2025 | Reblozyl, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $249.84 | 2022-2025 | Opdivo |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $197.60 | 2023-2025 | Trodelvy |
| Allergan, INC. | $190.53 | 2022 | |
| Tersera Therapeutics LLC | $183.63 | 2023-2025 | Zoladex |
| Incyte Corporation | $179.50 | 2021-2025 | Monjuvi, Jakafi, Zynyz |
| Takeda Pharmaceuticals U.S.A., INC. | $175.74 | 2022-2025 | Fruzaqla, Ninlaro |
| Array Biopharma INC | $163.42 | 2022-2025 | Mektovi, Braftovi, Tukysa |
| Servier Pharmaceuticals LLC | $156.87 | 2021-2025 | |
| Astellas Pharma US INC | $155.97 | 2021-2025 | Vyloy, Xospata, Padcev |
| Taiho Oncology, INC. | $153.32 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $152.53 | 2021-2025 | Ultomiris |
| Amgen INC. | $150.12 | 2021-2023 | Blincyto, Kyprolis, Lumakras |
| Pharmacosmos Therapeutics INC. | $143.94 | 2024-2025 | Monoferric, Cosela |
| Genentech USA, INC. | $129.76 | 2022-2025 | Polivy, Itovebi, Kadcyla |
| Regeneron Healthcare Solutions, INC. | $113.96 | 2022-2025 | Libtayo, Lynozyfic |
| Foundation Medicine, INC. | $108.13 | 2021 | |
| Jazz Pharmaceuticals INC. | $103.18 | 2022-2025 | |
| Morphosys, US INC. | $101.27 | 2022-2024 | Monjuvi |
| Stemline Therapeutics INC. | $100.59 | 2023-2025 | Orserdu |
| Janssen Pharmaceuticals, INC | $96.91 | 2023 | Xarelto |
| Beone Medicines USA, INC. | $95.24 | 2025 | Brukinsa, Tevimbra |
| Aveo Pharmaceuticals, INC. | $88.55 | 2021-2025 | |
| Sobi, INC | $80.81 | 2024-2025 | |
| Abbvie INC. | $80.39 | 2024-2025 | |
| Puma Biotechnology, INC. | $78.41 | 2022-2024 | |
| Agios Pharmaceuticals, INC. | $68.10 | 2021-2025 | Pyrukynd |
| Exelixis INC. | $64.16 | 2024-2025 | Cabometyx |
| Revance Therapeutics, INC. | $61.32 | 2025 | Daxxify |
| Genmab U.S., INC. | $59.90 | 2025 | Epkinly |
| G1 Therapeutics, INC. | $58.04 | 2022-2023 | Cosela |
| Pharmaessentia USA Corporation | $47.52 | 2022-2024 | Besremi |
| Ipsen Biopharmaceuticals, INC | $46.48 | 2023-2025 | Onivyde, Somatuline Depot |
| Mirati Therapeutics, INC. | $45.50 | 2024 | Krazati |
| Sumitomo Pharma America, INC. | $44.67 | 2023-2025 | Orgovyx |
| Iovance Biotherapeutics, INC. | $42.85 | 2025 | Amtagvi |
| Novocure INC. | $39.33 | 2025 | Optune Gio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.28 | 2021-2025 | |
| Abiomed | $33.57 | 2024 | Impella |
| Rigel Pharmaceuticals, INC. | $32.54 | 2021-2022 | |
| Epizyme, INC. | $29.09 | 2022 | |
| Csl Behring | $28.60 | 2023 | Afstyla, Idelvion |
| Apellis Pharmaceuticals, INC. | $27.09 | 2022 | |
| Emmaus Medical, INC. | $21.66 | 2021 | |
| Azurity Pharmaceuticals, INC. | $21.11 | 2025 | Danziten |
| Blue Earth Diagnostics | $20.83 | 2021 | |
| Immunocore Limited | $20.05 | 2025 | Kimmtrak |
| Emd Serono, INC. | $18.72 | 2025 | |
| Sun Pharmaceutical Industries INC. | $15.25 | 2021 | |
| Deciphera Pharmaceuticals INC. | $12.70 | 2023 | Qinlock |
| Global Blood Therapeutics, INC. | $12.46 | 2022 | |
| Myovant Sciences INC. | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.